Sarepta halts three studies testing gene therapy for muscle disorder-March 2024-www.financetom.com

Sarepta halts three studies testing gene therapy for muscle disorder

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sarepta halts three studies testing gene therapy for muscle disorder

Apr 4, 2025 6:16 AM

April 4 (Reuters) - Sarepta Therapeutics ( SRPT ) said

on Friday it would temporarily halt three trials testing its

gene therapy Elevidys.

Last month, the company said a 16-year-old boy died from

acute liver failure months after receiving the gene therapy for

a rare muscular dystrophy.

Previous page： Top Premarket Gainers Next page： Bitdeer Technologies Group's Q2 Loss Narrows, Revenue Rises

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Top Premarket Gainers

Aug 12, 2024

07:39 AM EDT, 08/12/2024 (MT Newswires) -- PS International ( PSIG ) shares surged 80% pre-bell Monday, extending Friday's rally. Veritone ( VERI ) advanced 18%, rebounding from Friday's slide. Nuburu ( BURU ) shares increased 7.3%, shaving losses from the previous session. Price: 3.6000, Change: +0.19, Percent Change: +5.57 ...

Bitdeer Technologies Group's Q2 Loss Narrows, Revenue Rises

Aug 12, 2024

07:36 AM EDT, 08/12/2024 (MT Newswires) -- Bitdeer Technologies Group ( BTDR ) reported a Q2 loss Monday of $0.14 per diluted share, narrower than its loss of $0.36 a year earlier. Analysts polled by Capital IQ expected earnings of $0.01. Revenue for the quarter ended June 30 was $99.2 million, compared with $93.8 million a year earlier. Analysts surveyed...

Fortrea Holdings Swings to Q2 Adjusted Loss; Revenue Falls; Shares Drop 7% Pre-Bell

Aug 12, 2024

07:42 AM EDT, 08/12/2024 (MT Newswires) -- Fortrea Holdings ( FTRE ) reported a Q2 adjusted loss Monday of $0.03 per diluted share, swinging from earnings of $0.52 a year earlier. Analysts surveyed by Capital IQ expected earnings of $0.06 per share. Revenue for the quarter ended June 30 was $662.4 million, compared with $725.1 million a year earlier. Analysts...

JetBlue Launches Senior Notes Offering, Term Loan

Aug 12, 2024

07:42 AM EDT, 08/12/2024 (MT Newswires) -- JetBlue Airways ( JBLU ) said Monday that it plans to offer $400 million of convertible senior notes due 2029. The carrier expects to grant initial purchasers a 13-day option to buy up to an additional $60 million of the notes. Net proceeds are expected to be used to repurchase a portion of...